NettetStandardized approaches to estimate lines of therapy were developed and evaluated in this study. A number of rules were developed, assumptions varied and macros developed to apply to large datasets. Results were investigated in an iterative process to refine line of therapy algorithms in three different cancers (lung, colorectal and gastric). Nettet14. apr. 2024 · Chemotherapy is associated with an increased risk of treatment-related heart damage, including heart failure and cerebrovascular disease, for many patients. …
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in ...
NettetPatients who received paclitaxel as second-line chemotherapy lived for an average of 462 days (95% confidence interval: 409–514), versus 405 days in the etoposide group … Nettet6. apr. 2024 · Patients treated with tremelimumab, durvalumab, and chemotherapy had a median overall survival of 14.0 versus 11.7 months with chemotherapy alone (hazard ratio, 0.77; 95% CI, 0.65 to 0.92). Grade 3-4 adverse effects were observed in 52% of patients treated with the combination and 44% treated with chemotherapy alone. ford ka 2004 é bom
Frontiers Real World Evidence on Second-Line Palliative Chemotherapy …
Nettet1. mai 2024 · From line 2, whether a patient had PR, SD or PD did not have an effect on chemotherapy-free interval. Number of previous lines and time from previous line were the only variables that significantly correlated with both outcome of patients and response to the next line. Nettet1. nov. 2024 · The standard second-line treatment often begins with salvage chemotherapy. “Most [salvage chemotherapy regimens] will have some effect in upwards of half of people with aggressive B-cell NHL, but salvage chemotherapy alone usually does not lead to long-lasting remission ,” said Dr. Melani. Nettet12. apr. 2024 · This is a randomized, double-blind, placebo-controlled, multicenter, Phase II study evaluating the efficacy and safety of ociperlimab in combination with tislelizumab and chemotherapy as first-line treatment for participants with advanced TNBC whose tumors express PD-L1 (CPS ≥ 10). ford ka acélfelni